Skip to main content

Table 2 Risk factors of systemic fungal infection

From: Oral nystatin prophylaxis to prevent systemic fungal infection in very low birth weight preterm infants: a randomized controlled trial

Variables

Nystatin group

Control group

p-value

(n = 47)

(n = 48)

 

Duration of stay in NICU, n (%)

 Mean duration time, days, mean (± SD)

9.8 (±14.9)

13.6 (±15.5)

0.23

  ≤ 7 days, n (%)

8 (17.0)

8 (16.7)

0.16

  > 7 days, n (%)

18 (38.3)

27 (56.3)

 

Use of peripheral venous access, n (%)

47 (100)

48 (100)

1.00

 Duration of peripheral venous access (days)

24 (6–42)

28 (5–62)

0.18

Use of central venous access, n (%)

38 (80.9)

37 (77.1)

0.80

 Duration of central venous access (days)

19 (0–42)

19 (0–42)

0.96

Use of orogastric tube, n (%)

47 (100)

47 (97.9)

1.00

 Duration of orogastric tube (days)

30 (8–42)

30 (8–42)

0.76

Use of endotracheal tube, n (%)

10 (21.3)

16 (33.3)

0.19

 Duration of endotracheal tube (days)

2.6 (0–21)

4.29 (0–31)

0.26

Use of antibiotic therapy, n (%)

43 (91.5)

46 (95.8)

0.44

 Duration of antibiotic therapy (days)

19 (0–42)

21 (0–42)

0.4

Use of aminophylline, n (%)

28 (59.6)

35 (72.9)

0.17

 Duration (days)

11 (1–42)

13 (3–42)

0.42

Use of steroid, n (%)

3 (6.4)

3 (6.3)

0.65

 Duration (days)

1 (0–12)

1 (0–3)

0.38

Use of parenteral nutrition, n (%)

45 (95.7)

47 (97.9)

0.62

 Duration (days)

21 (0–41)

22 (0–42)

0.53

 Duration of parenteral lipid (days)

16 (0–40)

19 (4–39)

0.15

  1. Data are presented in median (range) or proportion